Similar articles

• Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.

  Reese ES, Daniel Mullins C, Beitelshees AL, Onukwugha E. Reese ES, et al. Pharmacotherapy. 2012 Apr;32(4):323-32. doi: 10.1002/j.1875-9114.2012.01048. Pharmacotherapy. 2012. PMID: 22461122 Free PMC article.
• Cost is not a barrier to implementing clopidogrel pharmacogenetics.

  Cavallari LH, Schumock GT. Cavallari LH, et al. Pharmacotherapy. 2012 Apr;32(4):299-303. doi: 10.1002/j.1875-9114.2012.01107.x. Pharmacotherapy. 2012. PMID: 22461119 No abstract available.
• Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.

  Kazi DS, Garber AM, Shah RU, Dudley RA, Mell MW, Rhee C, Moshkevich S, Boothroyd DB, Owens DK, Hlatky MA. Kazi DS, et al. Ann Intern Med. 2014 Feb 18;160(4):221-32. doi: 10.7326/M13-1999. Ann Intern Med. 2014. PMID: 24727840
• Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).

  Wynn RL. Wynn RL. Gen Dent. 2010 Jan-Feb;58(1):7-9. Gen Dent. 2010. PMID: 20129886 Review. No abstract available.
• Prasugrel (Effient) vs. clopidogrel (Plavix).

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2009 Sep 7;51(1320):69-70. Med Lett Drugs Ther. 2009. PMID: 19738549 Review.